RESUMEN
Building on the gains of May Measurement Month 2017 (MMM17), the Philippine Society of Hypertension once again took part in MMM18 to raise awareness of high blood pressure (BP) in the country and to harness opportunistic BP screening in detecting unaware hypertensive individuals and referring them for treatment. We followed the standard MMM18 protocol designed by the International Society of Hypertension, utilizing convenience sampling with volunteer investigators, taking three sitting BP measurements of volunteer adults (≥18 years). Basic data on demographic, lifestyle, and environmental factors were also taken. We analysed 177 176 screened individuals from the Philippines. Of these, 29.1% (51 527) had also participated in MMM17, whereas 68.8% (121 893) were new screenees; and 14.2% (25 232) had their BP taken for the first time ever. After multiple imputation, 39.0% (69 126) were hypertensive. Of these, 50.3% (34 795) were aware they were hypertensive. 49.9% (34 491) were on antihypertensive medication, 58.0% (20 010) of whom had controlled BP <140/90 mmHg. Only 28.9% of all participants with hypertension had controlled BP. Systolic BPs and diastolic BPs were significantly higher in the overweight and obese, in those receiving antihypertensive medications, in patients with diabetes, and significantly lower in pregnant women. MMM18 has again shown that opportunistic BP screening, harnessing volunteers, is a pragmatic public health measure to improve awareness and treatment rates of raised BP.
RESUMEN
AIMS: In this paper, we discuss the existing data on the burden of hypertension in the Philippines and present the status of management, prevention, and control of hypertension in the country. METHODS: A literature review was conducted to synthesize the status of hypertension care in the Philippines. RESULTS: Hypertension continues to contribute to the country's leading causes of death. Similar to the global trend, almost half of hypertensive Filipinos are still not aware of their condition, and only 27 % have it under control. The prevalence of hypertension has steadily increased from 22 % in 1993 to 25.15 % in 2013. The 2020 Philippine Society for Hypertension clinical practice guideline defines hypertension as an office BP of 140/90 mm Hg or above following the proper standard BP measurement. During the past decade, monotherapy has been the mode of treatment in more than 80 % of Filipino patients. This could also explain why the BP control rates have been low. The most prevalent complications of hypertension in the Philippines were stroke (11.6 %), ischemic heart disease (7.7 %), chronic kidney disease (6.30 %), and hypertensive retinopathy (2.30 %). Hypertension causes economic tolls on patients, from the cost of drugs to hospitalization and complications. Hospitalization from hypertensive complications can easily wipe out the savings of middle-class families and is catastrophic for lower-income Filipinos. CONCLUSION: In this review, we summarize the existing data on the burden of hypertension among Filipinos and the risk factors associated with the disease. We present the current screening tools, diagnostics, treatment, and prevention strategies for hypertension in the Philippines. Lastly, we propose solutions to meet the global targets of hypertension management and help relieve the growing burden of this disease.
Asunto(s)
Hipertensión , Humanos , Hipertensión/epidemiología , Hipertensión/terapia , Filipinas/epidemiología , Manejo de la Enfermedad , Antihipertensivos/uso terapéutico , Prevalencia , PronósticoRESUMEN
The human papillomavirus (HPV) is the most common sexually transmitted infection in the United States, and the prevalence rate of infections is approximately 79 million. Research investigating HPV vaccine acceptability has primarily focused on female populations. The current study investigates factors associated with HPV vaccine acceptability in an underrepresented population within the literature, Hispanic males. Ninety-seven male participants (Mage = 21.68 years; SD = 3.97) were recruited from a large urban university along the U.S./Mexico border to complete a 15- to 20-minute survey. More than half of the sample reported to have had a sexual experience within the past 12 months and a fifth of these participants reported that they never use protection such as condoms. Furthermore, about half of the sample reported that they did not receive the HPV vaccine or were unaware if they received the HPV vaccine. A strong correlation emerged between individual vaccine risk perceptions and family vaccine risk perceptions (r = .82; p < .001). The following factors emerged as predictors of vaccine acceptability: having recommendations from health care providers, having a family with positive attitudes toward vaccines, and having a family that perceives less risks associated with vaccines. Implications of the findings are discussed.
Asunto(s)
Alphapapillomavirus , Infecciones por Papillomavirus , Vacunas contra Papillomavirus , Adulto , Femenino , Conocimientos, Actitudes y Práctica en Salud , Hispánicos o Latinos , Humanos , Masculino , México , Infecciones por Papillomavirus/prevención & control , Aceptación de la Atención de Salud , Estados Unidos , Vacunación , Adulto JovenRESUMEN
Dyslipidemia is a cardiovascular risk factor that is increasing in prevalence in the country. The need to treat and manage elevated cholesterol levels, both pharmacologic and non-pharmacologic, is of utmost importance. Different medical societies and groups bonded together to formulate the 2020 Philippine Clinical Practice Guidelines for dyslipidemia. The group raised nine clinical questions that are important in dyslipidemia management. A technical working group analyzed the clinical questions dealing with non-pharmacologic management, primary prevention for both non-diabetic and individuals with diabetes, familial hypercholesterolemia, secondary prevention, adverse events of statins and the use of other lipid parameters as measurement of risk for cardiovascular disease. Randomized controlled trials and meta-analyses were included in the GRADE-PRO analysis to come up with the statements answering the clinical questions. The statements were presented to a panel consisting of government agencies, members of the different medical societies, and private institutions, and the statements were voted upon to come up with the final statements of the 2020 practice guidelines. The 2020 CPG is aimed for the Filipino physician to confidently care for the individual with dyslipidemia and eventually lower his risk for cardiovascular disease.
RESUMEN
Hypertension is the most common cause of death and disability worldwide with its prevalence rising in low to middle income countries. It remains to be an important cause of morbidity and mortality in the Philippines with poor BP control as one of the main causes. Different societies and groups worked and collaborated together to develop the 2020 Philippine Clinical Practice Guidelines of hypertension arising for the need to come up with a comprehensive local practice guideline for the diagnosis, treatment, and follow up of persons with hypertension. A technical working group was organized into six clusters that analyzed the 30 clinical questions commonly asked in practice, looking into the definition of hypertension, treatment thresholds, blood pressure targets, and appropriate medications to reach targets. This guideline also includes recommendations for the specific management of hypertension among individuals with uncomplicated hypertension, hypertension among those with diabetes, stroke, chronic kidney disease, as well as hypertension among pregnant women and pediatric populations. It also looked into the appropriate screening and monitoring of patients when managing hypertension, and identification of groups who are at high risk for cardiovascular (CV) events. The ADAPTE process was used in developing the statements and recommendations which were then presented to a panel of experts for discussion and approval to come up with the final statements. This guideline aims to aid Filipino healthcare professionals to provide evidence-based care for persons with hypertension and help those with hypertension adequately control their blood pressure and reduce their CV risk.
Asunto(s)
Hipertensión , Presión Sanguínea , Niño , Femenino , Humanos , Hipertensión/diagnóstico , Hipertensión/tratamiento farmacológico , Hipertensión/epidemiología , Tamizaje Masivo , Filipinas/epidemiología , EmbarazoRESUMEN
A known cerebral palsy young man presented with prolonged bouts of generalised body movements associated with high-grade fever without any localising signs of infection, requiring multiple hospital admissions over several months. All septic work-ups, including a lumbar puncture, were negative. Serum chemistry was consistent with rhabdomyolysis. Repeated electroencephalograms showed no epileptiform discharges. Cranial MRI with gadolinium contrast revealed left cerebral atrophy with hyperintensities at the left basal ganglia. Uncontrolled dystonia with concomitant rhabdomyolysis was considered. Subsequent aggressive hydration and administration of muscle relaxant afforded abrupt resolution of symptoms.
Asunto(s)
Baclofeno/administración & dosificación , Parálisis Cerebral/complicaciones , Trastornos Distónicos/etiología , Fluidoterapia , Relajantes Musculares Centrales/administración & dosificación , Parálisis Cerebral/tratamiento farmacológico , Parálisis Cerebral/fisiopatología , Diagnóstico Diferencial , Trastornos Distónicos/tratamiento farmacológico , Trastornos Distónicos/fisiopatología , Electromiografía , Humanos , Imagen por Resonancia Magnética , Masculino , Rabdomiólisis , Resultado del Tratamiento , Adulto JovenRESUMEN
Angiotensin-converting enzyme 2 (ACE2) is an enzymatically active homologue of angiotensin-converting enzyme that degrades angiotensin I, angiotensin II, and other peptides. Recent studies have shown that under pathologic conditions, ACE2 expression in the kidney is altered. In this review, we briefly summarize recent studies dealing with pharmacologic interventions that modulate ACE2 expression. ACE2 amplification may have a potential therapeutic role for kidney disease and hypertension.
Asunto(s)
Angiotensina II/biosíntesis , Angiotensina I/biosíntesis , Hipertensión/tratamiento farmacológico , Peptidil-Dipeptidasa A/biosíntesis , Peptidil-Dipeptidasa A/efectos de los fármacos , Angiotensina I/efectos de los fármacos , Angiotensina II/efectos de los fármacos , Bloqueadores del Receptor Tipo 1 de Angiotensina II/uso terapéutico , Enzima Convertidora de Angiotensina 2 , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Antihipertensivos/uso terapéutico , Progresión de la Enfermedad , Humanos , Hipertensión/complicaciones , Receptor de Angiotensina Tipo 1/efectos de los fármacos , Sistema Renina-Angiotensina/efectos de los fármacosRESUMEN
Management of hypertension in diabetes is critical for reduction of cardiovascular mortality and morbidity. While blood pressure (BP) control has improved over the past two decades, the control rate is still well below 50% in the general population of patients with type 2 diabetes mellitus (T2DM). A new class of oral glucose-lowering agents has recently been approved; the sodium-glucose co-transporter 2 (SGLT2) inhibitors, which act by eliminating large amounts of glucose in the urine. Two agents, dapagliflozin and canagliflozin, are currently approved in the United States and Europe, and empagliflozin and ipragliflozin have reported Phase 3 trials. In addition to glucose lowering, SGLT2 inhibitors are associated with weight loss and act as osmotic diuretics, resulting in a lowering of BP. While not approved for BP-lowering, they may potentially aid BP goal achievement in people within 7-10 mm Hg of goal. It should be noted that the currently approved agents have side effects that include an increased incidence of genital infections, predominantly in women. The approved SGLT2 inhibitors have limited use based on kidney function and should be used only in those with an estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m2 for dapagliflozin and ≥45 mL/min/1.73 m2 for canagliflozin. Cardiovascular outcome trials are ongoing with these agents and will be completed within the next 4-5 years.
Asunto(s)
Presión Sanguínea/efectos de los fármacos , Hipoglucemiantes/uso terapéutico , Inhibidores del Cotransportador de Sodio-Glucosa 2 , Compuestos de Bencidrilo/uso terapéutico , Glucemia/metabolismo , Presión Sanguínea/fisiología , Peso Corporal/efectos de los fármacos , Canagliflozina , Glucósidos/uso terapéutico , Humanos , Riñón/fisiología , Reabsorción Renal/efectos de los fármacos , Reabsorción Renal/fisiología , Tiofenos/uso terapéuticoRESUMEN
Resistant hypertension defined as requiring 3 or more complementary antihypertensive drugs at maximally tolerated doses accounts for approximately 3% to 4% of all cases of hypertension. Its increased incidence over the past decade is related to the increase in obesity in the Western world. There are a number of dietary factors that affect sympathetic tone including sodium intake apart from increased body mass. This article discusses the mechanisms of sympathetic stimulation and activation in the context of animal models and human studies. In addition, there is a review of clinical trials with and without device therapy that summarizes the clinical findings. Effective management should be based on pathophysiologic principles and a focus on blood pressure reduction to levels well below 150/90 mm Hg because outcome trial evidence and Food and Drug Administration guidance supports this construct. The key to success of device-based therapy depends on identifying the cohort with true resistant hypertension that can benefit from therapies that are adjuncts to pharmacotherapy. Physicians need to concentrate on educating the patient on lifestyle modifications and themselves on use of proper combinations of antihypertensive medications. If this approach fails to result in a safe level of blood pressure then the patient should be referred to a board-certified clinical hypertension specialist.
Asunto(s)
Terapia por Estimulación Eléctrica , Hipertensión/fisiopatología , Hipertensión/terapia , Simpatectomía , Sistema Nervioso Simpático/fisiopatología , Animales , Barorreflejo/fisiología , Presión Sanguínea , Vasoespasmo Coronario/fisiopatología , Vasoespasmo Coronario/terapia , Resistencia a Medicamentos , Humanos , Estilo de Vida , Presorreceptores/fisiopatología , Sodio en la DietaRESUMEN
The beneficial effects of nebivolol on arterial stiffness and endothelial dysfunction are well documented in untreated hypertensive patients and differ from nonvasodilatory ß-blockers. This study tests the hypothesis that the addition of nebivolol in predominantly African American patients with type 2 diabetes already receiving maximally tolerated doses of renin-angiotensin system (RAS) blockers will further improve large artery compliance. Patients with type 2 diabetes and hypertension on maximal RAS blockade (n=70) were randomized to nebivolol or metoprolol succinate daily. Doses were titrated until systolic blood pressure (SBP) was <130 mm Hg. Radial artery applanation tonometry and pulse wave velocity (PWV) analysis were used to derive central aortic pressures and hemodynamic indices at repeated visits at intervals during a 6-month period. Both metoprolol succinate and nebivolol groups demonstrated reductions in brachial SBP (-8.2±4.3 mm Hg [P=.01] and -7.8±3.7 [P=.002], respectively) and aortic DBP (-2.4±1.8 [P=.039] and -4.0±2.9 mm Hg [P=.013], respectively). Aortic SBP decreased in the nebivolol group only (125.3±8 to 121.6±8.2, P=.025). There were no between group differences in aortic SBP, DBP, augmentation index, or PWV reduction. A significant increase in hemoglobin A1c was observed only in the metoprolol group. In patients with well-controlled type 2 diabetes and hypertension treated with maximally tolerated RAS blockade, nebivolol does not offer significant reductions in aortic BP over metoprolol succinate but maintains a stable metabolic profile.
Asunto(s)
Antagonistas de Receptores Adrenérgicos beta 1/uso terapéutico , Aorta/fisiología , Benzopiranos/uso terapéutico , Presión Sanguínea/fisiología , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Etanolaminas/uso terapéutico , Hemodinámica/fisiología , Hipertensión/tratamiento farmacológico , Sistema Renina-Angiotensina/fisiología , Antagonistas de Receptores Adrenérgicos beta 1/farmacología , Negro o Afroamericano , Anciano , Antagonistas de Receptores de Angiotensina/farmacología , Antagonistas de Receptores de Angiotensina/uso terapéutico , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Aorta/efectos de los fármacos , Benzopiranos/farmacología , Presión Sanguínea/efectos de los fármacos , Comorbilidad , Diabetes Mellitus Tipo 2/epidemiología , Diabetes Mellitus Tipo 2/fisiopatología , Etanolaminas/farmacología , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Frecuencia Cardíaca/fisiología , Hemodinámica/efectos de los fármacos , Humanos , Hipertensión/epidemiología , Hipertensión/fisiopatología , Lisinopril/farmacología , Lisinopril/uso terapéutico , Losartán/farmacología , Losartán/uso terapéutico , Masculino , Metoprolol/análogos & derivados , Metoprolol/farmacología , Metoprolol/uso terapéutico , Persona de Mediana Edad , Nebivolol , Sistema Renina-Angiotensina/efectos de los fármacos , Resultado del TratamientoRESUMEN
Hypertension is common in people aged 65 and older. African Americans and women have a higher prevalence of hypertension than white individuals, and in those aged 70 and older, the hypertension was more poorly controlled than in those aged 60-69. The number of trials available in the elderly population compared with the general population are limited; hence, the database for strong recommendations as to goal blood pressure (BP) are limited. The American College of Cardiology with the American Heart Association has recently published a consensus report of management of hypertension in the elderly population. This review presents an overview of this consensus report and reviews specific studies that provide some novel findings regarding goal BP and progression of nephropathy. In general, the evidence strongly supports a BP goal of less than 150/80 mmHg. The evidence review for the consensus report supports a goal of <150/80 mmHg for the elderly with scant data in those over age 80. However, it was decided to set the goal to less than 140/90 mmHg unless the patient cannot tolerate it and then try for 140-145 mmHg. The data are scant at best for those over age 80 mmHg but some evidence exists for <150/80 mmHg. Diuretics and calcium antagonists are the most efficacious single agents for treatment; however, most patients will require two or more drugs to achieve such goals.